Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 5 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa). This prevents fibrin formation and clot propagation. It also inhibits factors IXa, XIa, and XIIa.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Continuous IV infusion: Initial bolus of 5,000 units, then 1,000 units/hour (25,000 units/24h) adjusted based on aPTT. Typical infusion rate 10-20 units/kg/hour.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
30–150 minutes (intravenous), dose-dependent; at therapeutic doses ~60 minutes; prolonged in hepatic disease.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal: negligible; biliary/fecal: negligible; primarily cleared by hepatic depolymerization and reticuloendothelial system uptake.
Category C
Category A/B
Anticoagulant
Anticoagulant